Dermatouch is an Ahmedabad-based direct-to-consumer dermocosmetics brand, founded in 2021, that sells clinically positioned skincare for pigmentation and acne; Wipro Consumer Care agreed to buy a 60% stake in 2026.

This Startup Deep Dive explains what Dermatouch does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Dermatouch in Brief

• What it is: Dermatouch is an Indian Dermatology-led skincare brand company based in Ahmedabad.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• Sells face washes, sunscreens, serums, moisturisers, soaps and other over-the-counter skincare focused on pigmentation, acne, brightening and sun protection.
• Face cleansers are the lead category, followed by sunscreens and serums.
• Offers a skin test on its site and sells through its own site, marketplaces and quick-commerce.
• Funding: About $1.07 million seed (reported, undated, investors not named).

Dermatouch Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Dermatouch?

Dermatouch operates in the Dermatology-led skincare brand space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Dermatouch.

• Sells face washes, sunscreens, serums, moisturisers, soaps and other over-the-counter skincare focused on pigmentation, acne, brightening and sun protection.
• Face cleansers are the lead category, followed by sunscreens and serums.
• Offers a skin test on its site and sells through its own site, marketplaces and quick-commerce.
• Sales volume rose from about 60,000 products a month two years earlier to more than 60,000 a day (company-stated).

The Origin Story of Dermatouch

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Anish Nagpal, Amit Purswani.
• Founded in 2021 by Anish Nagpal and Amit Purswani (one outlet spells the second name Khuswani), based in Ahmedabad.
• Built as a digital-first, made-in-India brand with efficacy-led, science-backed positioning.
• Uses contract manufacturers for now, with possible Indian manufacturing later.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Dermatology-led skincare brand sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2021: Company founded.
• Seed round of about $1.07 million reported (date and investors not given).
• FY26: Revenue Rs 131 crore, up 114% on FY25.
• August 2026: Wipro Consumer Care & Lighting announced the acquisition of a 60% stake, its first acquisition of a digitally native beauty brand.

Dermatouch Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Seed round of about $1.07 million (reported, undated, investors not named).
• Wipro deal: 60% bought up front at enterprise value Rs 387.5 crore; remaining 40% over three years at a price tied to performance (undisclosed).

How Does Dermatouch Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Direct-to-consumer and marketplace sales, with 85-88% of consumer reviews coming from online channels.
• Offline presence is limited but growing, and general trade is growing faster than the overall business.
• Asset-light: manufacturing is outsourced to contract manufacturers.

The Numbers: Dermatouch Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• FY26: revenue Rs 131 crore (about $13.6 million), up 114% over FY25 (implies roughly Rs 61 crore in FY25).
• Profitability not disclosed.

Market Opportunity for Dermatouch

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Competes in India's fast-growing D2C skincare segment against dermo-cosmetic and active-ingredient brands.
• Founders cited Rs 1,000 crore as an illustrative ambition, not a firm target.

Technology and Product at Dermatouch

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Online skin test for product recommendation; digital-first sales and marketing.
• Wipro to add R&D and large-scale distribution strengths.

Team and Culture at Dermatouch

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Anish Nagpal and Amit Purswani continue to run the business with the existing management team.
• About 130 employees listed by one job platform.

Dermatouch Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Dermatouch

• Heavy reliance on online channels and quick-commerce, with limited offline reach.
• Fast growth in a crowded D2C category with many similar active-ingredient brands.
• Outsourced manufacturing; profitability not disclosed.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Dermatouch Growth Outlook: What to Watch

• Wipro plans to scale the brand by combining digital and physical distribution.
• Founders aim to make Dermatouch a global brand; remaining 40% stake to be acquired over three years.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Dermatouch can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Dermatouch Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Dermatouch

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Dermatouch.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Dermatouch

Studying a company in the Dermatology-led skincare brand space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Dermatouch.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Dermatouch as a Startup

• Customer clarity: Can Dermatouch name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Dermatouch is part of India’s growing Dermatology-led skincare brand ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Dermatouch FAQs: Frequently Asked Questions

What is Dermatouch?

Dermatouch is an Ahmedabad-based direct-to-consumer dermocosmetics brand, founded in 2021, that sells clinically positioned skincare for pigmentation and acne; Wipro Consumer Care agreed to buy a 60% stake in 2026. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Dermatouch?

Dermatouch was founded by Anish Nagpal, Amit Purswani, and the company reports a founding year of 2021.

How much funding has Dermatouch raised?

About $1.07 million seed (reported, undated, investors not named). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Dermatouch make money?

Dermatouch earns revenue from its Dermatology-led skincare brand products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Dermatouch?

Reported rivals include The Derma Co, Minimalist, Dot & Key, Foxtale and Clinikally. See the competitor comparison above for how they differ.

What are the main risks for Dermatouch?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Arthan Finance — Arthan Finance: Rs 50 Cr Series B for nano-MSME lending | Sarva — Celeb-backed yoga startup Sarva raised Rs 20 crore in 2019. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.